Oral probiotics increased the proportion of Treg, Tfr, and Breg cells to inhibit the inflammatory response and impede gestational diabetes mellitusOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers examined how gut microbiota dysbiosis drives gestational diabetes mellitus (GDM) and whether oral probiotics could correct it. They combined metagenomic and transcriptome sequencing of human SRA data with a mouse model of GDM.
How was it studied?
GDM and control metagenomic data from the SRA database were analyzed with KEGG pathway mapping, alongside transcriptome sequencing of GDM related gene expression. High fat, high sugar diet induced GDM mice then received oral Bifidobacterium strains FTJS7K1 and FTJS5K1 (1 times 10 to the 9th CFU/mL, 10 mL/kg) once daily for 7 days, with inflammatory markers, regulatory immune cells, and leptin measured afterward.
What did they find?
GDM patients had more Fusobacteria and Firmicutes while healthy controls had more Bacteroidetes, with altered L aspartate and L asparagine pathways and mannan degradation linked to leptin overexpression. Oral probiotics lowered leptin from 48.27 to 20.12 ng/mL, reduced TNF-alpha and IL-6, raised TGF-beta and IL-10, and increased the proportions of Treg, Tfr, and Breg cells compared with untreated GDM mice.
Why it matters
The findings suggest gut dysbiosis promotes GDM partly through leptin driven inflammation, and that targeted probiotic supplementation can restore regulatory immune balance and preserve normal pregnancy in this mouse model.